Korean J Transplant.  2022 Nov;36(Supple 1):S67. 10.4285/ATW2022.F-1832.

Prevalence of persistent hyperparathyroidism after renal transplantation in Myanmar

• Lin KZ

• KMID: 2535485
• DOI: http://doi.org/10.4285/ATW2022.F-1832

Abstract

Background
Organ transplantation is an effective therapy for end-stage organ failure and is widely practiced around the world. Successful renal transplantation corrects the abnormalities of mineral metabolism that lead to mineral bone disease. Howev-er, the degree of renal function recovery is usually incomplete, and persistence of hyperparathyroidism is common. Persistent hyperparathyroidism after renal transplantation in Myanmar population are incompletely known. This is the first clinical trial in Myanmar to evaluate the persistent hyperparathyroidism in kidney transplant recipients.
Methods
This is hospital based, single center, descriptive study. Consecutive sampling was used to recruit patients at visit to the DSGH renal transplant clinic over a period of 18 months. Persistent hyperparathyroidism is defined as iPTH greater than 65 pg/ mL after 3 months of transplantation.
Results
This study found that 77 out of 107 (72%) KTR patients demonstrated persistent hyperparathyroidism. In this study, mean iPTH level was 96.75±63.9 pg/mL with minimum of 25.1 pg/mL and maximum of 443.2 pg/mL. Normal level of iPTH is 15–65 pg/mL. Most of patients 50 (46.7%) were in CKD stage 2T and second most 33 patients were in CKD stage 3A T (30.8%). Only six (5.6%) patients were in advanced CKD stage 4T and 5T. Patients with posttransplant eGFR were negative correlation with posttransplant persistent hyperthyroidism (P=0.032). Patients with longer duration of CKD prior to transplantation had increased risk of developing posttransplant hyperparathyroidism. Low vitamin D status (<30 ng/mL) was noted in 56 patients (72.7%).
Conclusions
High prevalence of persistent hyperparathyroidism (about 72%) was observed in Myanmar renal transplant recip-ients despite the recipients healthy allograft function. It is hoped that this study will contribute some information in the clinical practice of posttransplant renal bone disease in our country.